246 related articles for article (PubMed ID: 32484937)
1. Cancer attributable to human papillomavirus infection in China: Burden and trends.
Lu Y; Li P; Luo G; Liu D; Zou H
Cancer; 2020 Aug; 126(16):3719-3732. PubMed ID: 32484937
[TBL] [Abstract][Full Text] [Related]
2. [Analysis on cancer incidence and mortality attributed to human papillomavirus infection in China, 2016].
Yuan MW; Wang HH; Duan RF; Xu KP; Hu SY; Qiao YL; Zhang Y; Zhao F
Zhonghua Liu Xing Bing Xue Za Zhi; 2022 May; 43(5):702-708. PubMed ID: 35589576
[No Abstract] [Full Text] [Related]
3. Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China.
Duan R; Qiao Y; Clifford G; Zhao F
Cancer Med; 2020 Jan; 9(1):374-384. PubMed ID: 31714036
[TBL] [Abstract][Full Text] [Related]
4. Patterns and trends of HPV-related cancers other than cervix in South Africa from 1994-2013.
Chikandiwa A; Pisa PT; Sengayi M; Singh E; Delany-Moretlwe S
Cancer Epidemiol; 2019 Feb; 58():121-129. PubMed ID: 30557819
[TBL] [Abstract][Full Text] [Related]
5. Temporal Trends and Projection of Cancer Attributable to Human Papillomavirus Infection in China, 2007-2030.
Duan R; Xu K; Huang L; Yuan M; Wang H; Qiao Y; Zhao F
Cancer Epidemiol Biomarkers Prev; 2022 May; 31(5):1130-1136. PubMed ID: 35266990
[TBL] [Abstract][Full Text] [Related]
6. Cancer incidence in Germany attributable to human papillomavirus in 2013.
Buttmann-Schweiger N; Deleré Y; Klug SJ; Kraywinkel K
BMC Cancer; 2017 Oct; 17(1):682. PubMed ID: 29037233
[TBL] [Abstract][Full Text] [Related]
7. Global burden of human papillomavirus and related diseases.
Forman D; de Martel C; Lacey CJ; Soerjomataram I; Lortet-Tieulent J; Bruni L; Vignat J; Ferlay J; Bray F; Plummer M; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F12-23. PubMed ID: 23199955
[TBL] [Abstract][Full Text] [Related]
8. The burden of HPV associated cancers in two regions in Nigeria 2012-2014.
Jedy-Agba EE; Dareng EO; Adebamowo SN; Odutola M; Oga EA; Igbinoba F; Otu T; Ezeome E; Bray F; Hassan R; Adebamowo CA
Cancer Epidemiol; 2016 Dec; 45():91-97. PubMed ID: 27780076
[TBL] [Abstract][Full Text] [Related]
9. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection.
Giuliano AR; Nyitray AG; Kreimer AR; Pierce Campbell CM; Goodman MT; Sudenga SL; Monsonego J; Franceschi S
Int J Cancer; 2015 Jun; 136(12):2752-60. PubMed ID: 25043222
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review.
Hartwig S; Syrjänen S; Dominiak-Felden G; Brotons M; Castellsagué X
BMC Cancer; 2012 Jan; 12():30. PubMed ID: 22260541
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
Mpunga T; Chantal Umulisa M; Tenet V; Rugwizangoga B; Milner DA; Munyanshongore C; Heideman DAM; Bleeker MCG; Tommasino M; Franceschi S; Baussano I; Gheit T; Sayinzoga F; Clifford GM
Int J Cancer; 2020 Mar; 146(6):1514-1522. PubMed ID: 31173641
[TBL] [Abstract][Full Text] [Related]
12. Worldwide burden of cancer attributable to HPV by site, country and HPV type.
de Martel C; Plummer M; Vignat J; Franceschi S
Int J Cancer; 2017 Aug; 141(4):664-670. PubMed ID: 28369882
[TBL] [Abstract][Full Text] [Related]
13. Worldwide trend in human papillomavirus-attributable cancer incidence rates between 1990 and 2012 and Bayesian projection to 2030.
Wu J; Xiao F; Zheng Y; Lin Y; Wang HL
Cancer; 2021 Sep; 127(17):3172-3182. PubMed ID: 33974715
[TBL] [Abstract][Full Text] [Related]
14. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
15. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
[TBL] [Abstract][Full Text] [Related]
16. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
17. Differences in Sociodemographic Correlates of Human Papillomavirus-Associated Cancer Survival in the United States.
Osazuwa-Peters N; Simpson MC; Rohde RL; Challapalli SD; Massa ST; Adjei Boakye E
Cancer Control; 2021; 28():10732748211041894. PubMed ID: 34696619
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.
Gilbert DC; Wakeham K; Langley RE; Vale CL
Br J Cancer; 2019 Jan; 120(2):256-268. PubMed ID: 30482913
[TBL] [Abstract][Full Text] [Related]
19. Infection of human papillomaviruses in cancers of different human organ sites.
Shukla S; Bharti AC; Mahata S; Hussain S; Kumar R; Hedau S; Das BC
Indian J Med Res; 2009 Sep; 130(3):222-33. PubMed ID: 19901431
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological features of Human Papillomavirus (HPV) infection among women living in Mainland China.
Li J; Huang R; Schmidt JE; Qiao YL
Asian Pac J Cancer Prev; 2013; 14(7):4015-23. PubMed ID: 23991946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
